- Bristol Myers Squibb ended its partnership with Cellares to expand manufacturing of its personalized blood cancer therapy Breyanzi.
- Bristol Myers said Cellares' Cell Shuttle platform could not meet the requirements to manufacture Breyanzi at commercial scale, while Cellares disputed that assessment.
- Cellares will lay off about 100 employees at its South San Francisco facility on October 20 after losing the large pharmaceutical customer.
- Breyanzi generated $1.36 billion in sales in 2025, and the 2024 partnership was valued at up to $380 million.
Quotes
“could not meet the requirements to make its CAR-T therapy, Breyanzi, at commercial scale”
“Cellares strongly disagrees with this characterization”
“large pharmaceutical customer”